Skip to main content
Top

Clinical & Experimental Metastasis

Issue 4/2015

Content (9 Articles)

Research Paper

MTBP inhibits migration and metastasis of hepatocellular carcinoma

Qian Bi, Atul Ranjan, Rui Fan, Neeraj Agarwal, Danny R. Welch, Steven A. Weinman, Jie Ding, Tomoo Iwakuma

Research Paper

Tumour growth of colorectal rat liver metastases is inhibited by hepatic arterial infusion of the mTOR-inhibitor temsirolimus after portal branch ligation

Jens Sperling, Christian Ziemann, Anika Gittler, Anna Benz-Weißer, Michael D. Menger, Otto Kollmar

Research Paper

Dietary soy isoflavones increase metastasis to lungs in an experimental model of breast cancer with bone micro-tumors

Xujuan Yang, Aashvini Belosay, James A. Hartman, Huaxin Song, Yukun Zhang, Wendan Wang, Daniel R. Doerge, William G. Helferich

Research Paper

Dormancy and growth of metastatic breast cancer cells in a bone-like microenvironment

Donna M. Sosnoski, Robert J. Norgard, Cassidy D. Grove, Shelby J. Foster, Andrea M. Mastro

Research Paper

Postoperative brain metastases in soft tissue sarcomas

Hiroshi Urakawa, Satoshi Tsukushi, Eiji Kozawa, Kunihiro Ikuta, Shunsuke Hamada, Naoki Ishiguro, Yoshihiro Nishida

Research Paper

Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer

Aimalie L. Hardaway, Mackenzie K. Herroon, Erandi Rajagurubandara, Izabela Podgorski

Research Paper

Growth pattern of colorectal liver metastasis as a marker of recurrence risk

R. L. Eefsen, P. B. Vermeulen, I. J. Christensen, O. D. Laerum, M. B. Mogensen, H. C. Rolff, G. G. Van den Eynden, G. Høyer-Hansen, K. Osterlind, B. Vainer, M. Illemann

Research Paper

Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis

D. Subirá, M. Simó, J. Illán, C. Serrano, S. Castañón, R. Gonzalo, J. J. Granizo, M. Martínez-García, M. Navarro, J. Pardo, J. Bruna

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine